Real-world rebound pattern of serum collagen type I C-telopeptide after denosumab discontinuation and zoledronate rescue in postmenopausal osteoporosis and cancer treatment-induced bone loss
Summary Stopping denosumab causes a temporary rebound in bone resorption, even when zoledronate is administered afterwards. We analyzed 65 women with postmenopausal osteoporosis or cancer treatment–induced bone loss who received a single zoledronate infusion 6 months after their…